Text Size:AAA

人 DLL4 蛋白 (Fc 標籤)

產品資料評論實驗方法
反應性: Human  
應用 : ELISA  
    10171-RP02-50
    10171-RP02-200
    10171-RP02-100
    50 µg 
    200 µg 
    100 µg 
    Add to Cart
    反應性: Human  
    應用 : ELISA  
      10171-MM15-50
      10171-MM15-200
      10171-MM15-100
      50 µg 
      200 µg 
      100 µg 
      Add to Cart
      反應性: Human  
      應用 : ELISA  
        10171-R003-50
        10171-R003-100
        10171-R003-1
        50 µg 
        100 µg 
        1 mg 
        Add to Cart
        反應性: Human  
        應用 : ELISA  
          10171-RP01-400
          10171-RP01-200
          10171-RP01-100
          400 µg 
          200 µg 
          100 µg 
          Add to Cart
          反應性: Human  
          應用 : ELISA  
            10171-MM06-50
            10171-MM06-200
            10171-MM06-100
            10171-MM06-1
            50 µg 
            200 µg 
            100 µg 
            1 mg 
            Add to Cart
            反應性: Mouse  
            應用 : ELISA  
              50640-R006-50
              50640-R006-100
              50 µg 
              100 µg 
              Add to Cart
              反應性: Mouse  
              應用 : ELISA  
                50640-RP01-400
                50640-RP01-200
                50640-RP01-100
                400 µg 
                200 µg 
                100 µg 
                Add to Cart
                反應性: Mouse  
                應用 : 
                  50640-R004-50
                  50640-R004-100
                  50640-R004-1
                  50 µg 
                  100 µg 
                  1 mg 
                  Add to Cart
                  反應性: Mouse  
                  應用 : ELISA  
                    50640-RP02-50
                    50640-RP02-200
                    50640-RP02-100
                    50 µg 
                    200 µg 
                    100 µg 
                    Add to Cart

                    DLL4/Delta-like 4 ELISA配對抗體

                    檢測限: 9.375 pg/ml
                    SEK50640-5
                    SEK50640-15
                    5 Plates 
                    15 Plates 
                    Add to Cart
                    檢測限: 31.25 pg/ml
                    SEK10171-5
                    SEK10171-15
                    5 Plates 
                    15 Plates 
                    Add to Cart

                    DLL4/Delta-like 4 Recombinant ProteinRelated Products

                    Related Products

                    Featured Reagent Products

                    DLL4/Delta-like 4 protein 研究背景

                    Delta-like protein 4 (DLL4, Delta4), a type I membrane-bound Notch ligand, is one of five known Notch ligands in mammals and interacts predominantly with Notch 1, which has a key role in vascular development. Recent studies yield substantial insights into the role of DLL4 in angiogenesis. DLL4 is induced by vascular endothelial growth factor (VEGF) and acts downstream of VEGF as a 'brake' on VEGF-induced vessel growth, forming an autoregulatory negative feedback loop inactivating VEGF. DLL4 is downstream of VEGF signaling and its activation triggers a negative feedback that restrains the effects of VEGF. Attenuation of DLL4/Notch signaling results in chaotic vascular network with excessive branching and sprouting. DLL4 is widely distributed in tissues other than vessels including many malignancies. Furthermore, the molecule is internalized on binding its receptor and often transported to the nucleus. In pathological conditions, such as cancer, DLL4 is up-regulated strongly in the tumour vasculature. Blockade of DLL4-mediated Notch signaling strikingly increases nonproductive angiogenesis, but significantly inhibits tumor growth in preclinical mouse models. In preclinical studies, blocking of DLL4/Notch signaling is associated with a paradoxical increase in tumor vessel density, yet causes marked growth inhibition due to functionally defective vasculature. Thus, DLL4 blockade holds promise as an additional strategy for angiogenesis-based cancer therapy.

                     DLL4/Delta-like 4 protein 參考資料
                  • Yan M, et al. (2007) Delta-like 4/Notch signaling and its therapeutic implications. Clin Cancer Res. 13(24): 7243-6.
                  • Sainson RC, et al. (2007) Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol Med. 13(9): 389-95.
                  • Martinez JC, et al. (2009) Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology. 54(5): 598-606.
                  • Li JL, et al. (2010) Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. Future Oncol. 6(7): 1099-103.
                  • 請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”